Table 3.
Cost-effective analysis results for base-case and sensitivity analyses
| Usual care control group | IDC group | IDC group vs. control group | |
|---|---|---|---|
| Base-case “within trial” analysis,an | 56 | 53 | |
| Mean cost per participant (95% CrI) | £11,097.00 (£6,191.21–£16,002.79) | £9678.30 (£4806.92–£14,459.68) | −£1418.40 (−£8589.76 to £5833.91) |
| Mean QALYs per participant (95% CrI) | 0.336 (0.280–0.391) | 0.349 (0.293–0.405) | 0.013 (−0.065 to 0.092) |
| Cost per QALY gained | −£106,538.48 | ||
| Probability CE @ £20,000 per QALY gained | 0.73 | ||
| Probability CE @ £30,000 per QALY gained | 0.73 | ||
| Base-case “within and posttrial” analysis,bn | 49 | 51 | |
| Mean cost per participant (95% CrI) | £25,334.00 (£13,640.04–£37,027.96) | £16,731.00 (£5714.95–£27,747.05) | −£8603.10 (−£23,361.71 to £7807.69) |
| Mean QALYs per participant (95% CrI) | 0.647 (0.518–0.776) | 0.713 (0.585–0.841) | 0.066 (−0.117 to 0.0.248) |
| Cost per QALY gained | −£118,184.42 | ||
| Probability CE @ £20,000 per QALY gained | 0.93 | ||
| Probability CE @ £30,000 per QALY gained | 0.94 | ||
| SA1,cn | 36 | 43 | |
| Mean cost per participant (95% CrI) | £10,276.00 (£6,645.45–£13,906.55) | £7733.10 (£4573.03–£10,892.22) | −£2541.70 (−£7046.03 to £2463.81) |
| Mean QALYs per participant (95% CrI) | 0.324 (0.249–0.399) | 0.343 (0.271–0.415) | 0.019 (−0.085 to 0.123) |
| Cost per QALY gained | −£120,104.45 | ||
| Probability CE @ £20,000 per QALY gained | 0.90 | ||
| Probability CE @ £30,000 per QALY gained | 0.90 | ||
| SA2,dn | 36 | 43 | |
| Mean cost per participant (95% CrI) | £23,464.00 (£15,000.20–£31,927.80) | £14,140.00 (£6985.24–£21,294.76) | −£9322.90 (−£18,355.11 to −£1601.31) |
| Mean QALYs per participant (95% CrI) | 0.625 (0.485–0.765) | 0.707 (0.572–0.842) | 0.082 (−0.111 to 0.276) |
| Cost per QALY gained | −£101,835.69 | ||
| Probability CE @ £20,000 per QALY gained | 0.98 | ||
| Probability CE @ £30,000 per QALY gained | 0.98 |
CE, cost-effective; CrI, credible interval; EQ-5D-5L, Euro QoL-5 dimension-5 level; GP, general practice; IDC, intradialytic cycling; QALY, quality-adjusted life year; SA, sensitivity analysis.
Six-month within trial analysis imputing for missing GP and EQ-5D-5L observations (excluding participants lost to follow-up during the first 6 months).
Zero to 12-month analysis (including 6 months posttrial) imputing for missing GP and EQ-5D-5L observations, and extrapolating EQ-5D-5L to 12 months (excluding participants lost to follow-up).
“Within trial” cost-utility analysis: 0-6 months within trial analysis imputing for missing GP observations (4 and 7 observations missing for the control group and the IDC group, respectively; excluding participants lost to follow-up during first 6 months and with missing EQ-5D-5L at ≥1 time point).
“Within and posttrial” cost-utility analysis: 0-12 month analysis imputing for missing GP observations (4 and 7 observations missing for the control group and the IDC group, respectively; excluding participants lost to follow-up and with missing EQ-5D-5L at ≥1 time point).